Love it, but…I think the ‘months needing treatment’ multiplier is a bit exuberant?
I can’t remember where I read this (so I could be wrong) but the Japan sales figures showed a high percentage of sales coming from new users, which to me indicated a low percentage of sales coming from repeat prescriptions. Either way my impression was that the product wasn’t being used as a daily thing.
Having said that I know Japan ain’t the US and there appears to be very different sales strategies. Would love it if someone with a better memory could confirm/deny my thoughts on the Japan repeat prescription numbers.
Ann: FDA Approves Sofdra, page-226
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.3¢ |
Change
0.003(0.68%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 37.0¢ | $329.6K | 890.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 169999 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 180585 | 15 |
View Market Depth
| Last trade - 11.16am 08/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |